Aptose Biosciences Inc (APTO) Receives $6.00 Consensus Target Price from Brokerages

Aptose Biosciences Inc (NASDAQ:APTO) (TSE:APS) has been given a consensus rating of “Hold” by the six brokerages that are currently covering the company, MarketBeat reports. One research analyst has rated the stock with a sell recommendation, two have given a hold recommendation and three have issued a buy recommendation on the company. The average 1 year price target among analysts that have issued a report on the stock in the last year is $6.00.

Several brokerages have commented on APTO. HC Wainwright set a $4.00 price objective on Aptose Biosciences and gave the company a “buy” rating in a report on Wednesday, November 15th. Zacks Investment Research raised Aptose Biosciences from a “sell” rating to a “hold” rating in a report on Monday, December 25th. ValuEngine lowered Aptose Biosciences from a “sell” rating to a “strong sell” rating in a report on Friday, December 1st. Canaccord Genuity set a $7.00 price objective on Aptose Biosciences and gave the company a “buy” rating in a report on Wednesday, November 15th. Finally, Roth Capital reissued a “buy” rating and issued a $5.00 price objective on shares of Aptose Biosciences in a report on Monday, October 23rd.

Shares of Aptose Biosciences (NASDAQ APTO) traded down $0.01 on Wednesday, reaching $2.68. The company’s stock had a trading volume of 165,100 shares, compared to its average volume of 504,339. Aptose Biosciences has a one year low of $0.78 and a one year high of $3.90. The firm has a market capitalization of $74.32, a price-to-earnings ratio of -4.06 and a beta of 2.84.

An institutional investor recently raised its position in Aptose Biosciences stock. Acadian Asset Management LLC raised its holdings in Aptose Biosciences Inc (NASDAQ:APTO) (TSE:APS) by 316.9% during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 44,421 shares of the biotechnology company’s stock after purchasing an additional 33,766 shares during the period. Acadian Asset Management LLC owned about 0.17% of Aptose Biosciences worth $100,000 at the end of the most recent quarter. 1.07% of the stock is currently owned by institutional investors and hedge funds.

COPYRIGHT VIOLATION WARNING: This piece of content was originally posted by Week Herald and is the property of of Week Herald. If you are accessing this piece of content on another site, it was illegally stolen and republished in violation of US & international copyright & trademark law. The legal version of this piece of content can be read at https://weekherald.com/2018/03/14/aptose-biosciences-inc-apto-receives-6-00-consensus-target-price-from-brokerages.html.

About Aptose Biosciences

Aptose Biosciences Inc (Aptose) is a clinical-stage biotechnology company. The Company is engaged in the development of anticancer drugs that target specific epigenetic processes and signal transduction abnormalities that underlie a particular life-threatening malignancy. Its product pipeline includes cancer drug candidates that exert activity as stand-alone agents and that enhance the activities of other anticancer agents without causing overlapping toxicities.

Receive News & Ratings for Aptose Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aptose Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply